Guggenheim Reiterates Buy Rating on Amylyx Pharmaceuticals
Guggenheim maintains its buy rating on Amylyx Pharmaceuticals with a $40 price target, a 122.22% upside from the current price.
Key Points
- Guggenheim reiterated its buy rating on Amylyx Pharmaceuticals, Inc. (AMLX) with a $40 price target on June 25, 2026.
- Guggenheim's $40 price target implies 122.22% upside from Amylyx Pharmaceuticals, Inc.'s ($AMLX) current $18 share price.
- Shares of AMLX traded near $18.45 on Friday, with a market cap of approximately $1.94 billion.
- Notable insider buying activity occurred on June 4, 2026, with several insiders acquiring 24,372 shares each.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 25, 2026, Guggenheim reiterated its buy rating on Amylyx Pharmaceuticals, Inc. (NasdaqGS: AMLX), setting a price target of $40. Analyst Seamus Fernandez maintains a positive outlook on the pharmaceutical company, which focuses on developing treatments for neurodegenerative diseases.
Amylyx Pharmaceuticals, Inc. Stock Down 48.2%
Shares of NasdaqGS:AMLX traded near $18.45 on Friday. Amylyx Pharmaceuticals has a market cap of approximately $1.94 billion. The company's stock has seen a 52-week low of $5.97 and a high of $18.74. The stock's 50-day moving average is around $15.18, while its 200-day moving average stands at about $14.19. Despite the company's current financial challenges, with a forward P/E ratio of -13.78 and a beta of -0.157, it maintains a strong liquidity position with a current ratio of 17.85.
$AMLX price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals saw a flurry of insider buying on June 4, 2026. Notable insiders, including George Milne Jr., Daphne Quimi, Karen Firestone, Bernhardt Zeiher, and Paul Fonteyne, each purchased 24,372 shares. Additionally, Karen Firestone acquired 3,800 shares on May 21, 2026, at an average price of $13.51 per share.
Analysts Set New Price Targets
On June 25, 2026, Guggenheim maintained its buy rating on Amylyx Pharmaceuticals with a $40 price target. Other analysts have also shown optimism, with Mizuho maintaining a buy rating at a $21 target on April 28, 2026, and HC Wainwright & Co. maintaining a buy rating with a $34 target on March 4, 2026. The consensus among analysts is a strong buy, with a mean target price of $24.4.
About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company headquartered in Cambridge, Massachusetts. Founded in 2013, the company is led by CEO Joshua B. Cohen and employs 136 people. It focuses on discovering and developing treatments for neurodegenerative diseases, with its flagship product, Avexitide, in phase 3 clinical trials. The company also develops AMX0035 for various neurological conditions and several other investigational drugs.
Bottom Line
Guggenheim's reiterated buy rating and $40 price target highlight continued confidence in Amylyx Pharmaceuticals' potential. Investors closely watch these ratings as a gauge of the company's future prospects. As always, it's important to remember that analyst ratings and price targets are based on backward-looking data and should be considered as one of many factors in making investment decisions.
Get Amylyx Pharmaceuticals, Inc. alerts
New 13F filings, insider trades, and analyst moves on $AMLX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.